Ensartinib

Drug Profile

Ensartinib

Alternative Names: X-396

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Xcovery
  • Developer Xcovery Holdings
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • No development reported Haematological malignancies

Most Recent Events

  • 17 Jan 2017 Xcovery collaborates with NCI Formulary to co-develop ensartinib in Cancer
  • 07 Nov 2016 Betta Pharmaceuticals plans a phase I trial for Solid tumours (Late-stage disease) and Non-small cell lung cancer in China (PO) (NCT02959619)
  • 16 Sep 2016 Ludwig Institute for Cancer Research, MedImmune, Xcovery and Cancer Research Institute, New York plan a phase I/II trial for Non-small cell lung cancer (Metastatic disease, Monotherapy, Combination therapy) in USA (PO) (NCT02898116)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top